Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery

References

• SinglaAKGargAAggarwalDPaclitaxel and its formulationsInt J Pharm20022351–217919211879753
   PubMed Web of Science ®Google Scholar
• AppendinoGTaxol (paclitaxel): historical and ecological aspectsFitoterapia199364Suppl 1525
   Google Scholar
• FoaRNortonLSeidmanATaxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activityInt J Clin Lab Res19942416147910054
   PubMedGoogle Scholar
• SpencerCFauldsDPaclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancerDrugs19944857947530632
   PubMed Web of Science ®Google Scholar
• ChervinskyDBrecherMHoelcleMCremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell lineAnticancer Res199313193968097392
   PubMed Web of Science ®Google Scholar
• WebsterLLinsenmeyerMMillwardMMortonCBishopJWoodcockDMeasurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotypeJ Natl Cancer Inst1993852016858105099
   PubMedGoogle Scholar
• FjällskogMLFriiLBerghJIs Cremophor EL, solvent for paclitaxel, cytotoxic?Lancet19933428875873
   PubMed Web of Science ®Google Scholar
• DorrRPharmacology and toxicology of Cremophor EL diluentAnn Pharmacother1994285S11147915152
   PubMedGoogle Scholar
• RowinskyEEisenhauerEChaudhryVArbuckSDonehowerRClinical toxicities encountered with paclitaxel (Taxol)Semin Oncol1993204 Suppl 31158102012
   PubMed Web of Science ®Google Scholar
• WeissRDonehowerRWiernikPHypersensitivity reactions from taxolJ Clin Oncol19908712631972736
   PubMed Web of Science ®Google Scholar
• BöhmBHLMüllerRHLab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugsPharm Sci Technol Today19992833633910441278
   PubMedGoogle Scholar
• PatravaleVDateAKulkarniRNanosuspensions: a promising drug delivery strategyJ Pharm Pharmacol200456782784015233860
   PubMed Web of Science ®Google Scholar
• RabinowBNanosuspensions in drug deliveryNat Rev Drug Discov20043978579615340388
   PubMed Web of Science ®Google Scholar
• HintzRJJohnsonKCThe effect of particle size distribution on dissolution rate and oral absorptionInt J Pharm1989511917
   Web of Science ®Google Scholar
• MüllerRHJacobsCKayserONanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the futureAdv Drug Deliv Rev200147131911251242
   PubMed Web of Science ®Google Scholar
• MullerRHKeckCMChallenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticlesJ Biotechnol20041131–315117015380654
   PubMed Web of Science ®Google Scholar
• MüllerRHPetersKNanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction techniqueInt J Pharm19981602229237
   Web of Science ®Google Scholar
• PetersKLeitzkeSDiederichsJPreparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infectionJ Antimicrob Chemother20004517710629016
   PubMed Web of Science ®Google Scholar
• Merisko-LiversidgeESarpotdarPBrunoJFormulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugsPharm Res19961322722788932448
   PubMed Web of Science ®Google Scholar
• LiXGuLXuYWangYPreparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in ratsDrug Dev Ind Pharm200935782783319466879
   PubMed Web of Science ®Google Scholar
• DengJHuangLLiuFUnderstanding the structure and stability of paclitaxel nanocrystalsInt J Pharm2010390224224920167270
   PubMed Web of Science ®Google Scholar
• MishraPRShaalLAMüllerRHKeckCMProduction and characterization of Hesperetin nanosuspensions for dermal deliveryInt J Pharm20093711–218218919162147
   PubMed Web of Science ®Google Scholar
• RouiniMLotfolahiAStewartDA rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere®) in human plasma using a column switching techniqueJ Pharm Biomed Anal1998178124312479800643
   PubMed Web of Science ®Google Scholar
• SparreboomAvan TellingenONoojienWJBeijnenJHDetermination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatographyJ Chromatogr B Biomed Sci Appl19956642383391
   Web of Science ®Google Scholar
• ClementMPughWParikhITissue distribution and plasma clearance of a novel microcrystalline-coated flurbiprofen formulationPharmacologist199234204
   Google Scholar
• GantaSPaxtonJWBaguleyBCGargSFormulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous deliveryInt J Pharm20093671–217918618848873
   PubMed Web of Science ®Google Scholar
• MoghimiSHunterAMurrayJLong-circulating and target-specific nanoparticles: theory to practicePharmacol Rev200153228311356986
   PubMed Web of Science ®Google Scholar
• DevalapallyHShenoyDLittleSLangerRAmijiMPoly (ethylene oxide)-modified poly (beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft modelCancer Chemother Pharmacol200759447748416862429
   PubMed Web of Science ®Google Scholar
• MaedaHMatsumuraYTumoritropic and lymphotropic principles of macromolecular drugsCritical reviews in therapeutic drug carrier systems1989631932692843
   PubMed Web of Science ®Google Scholar
• GaoLZhangDChenMStudies on pharmacokinetics and tissue distribution of oridonin nanosuspensionsInt J Pharm20083551–232132718242896
   PubMed Web of Science ®Google Scholar
• ManjunathKVenkateswarluVPharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administrationJ Control Release2005107221522816014318
   PubMed Web of Science ®Google Scholar